Yang JC, Ohe Y, Chiu CH, Ou X, et al. Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clin Cancer Res 2022 Jun 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-21-4329.
PMID: 35735998